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Abstract                                                                                                                           
Background and aims: Drug induced autoimmune hepatitis (DIAIH) remains poorly 
characterised. Our aim was to assess natural history and outcomes in DIAIH.                                                                                                                            
Methods: Retrospective cohort study.                                                                                                
Results: Eighty-two patients with AIH identified, 11 (13.4 %) having DIAIH, implicated 
drugs being nitrofurantoin (n=4), statins (n=4), herbal remedies (n=2), and diclofenac (n=1). 
Female gender (81.8% vs. 80.3%), acute onset (54.5% vs. 46.5%), elevated serum 
globulins/IgG (72.7% vs. 75.4%), fibrosis stage (Ishak) (2.8 +1.8 vs. 3.6 +2.0), cirrhosis at 
onset (27.2% vs. 35.2%), moderate-severe portal inflammation (81.8% vs. 82.2%), interface 
(54.5% vs. 63.9%) and lobular hepatitis (63.6% vs. 59%), remission (100% vs. 92.4%), 
relapse (60% vs. 83.3%) and poor outcome (18.2% vs. 36.6%) were similar in those with 
DIAIH and AIH (p>0.05). The former were however more likely to be aged > 60 yrs (72.7% 
vs. 40.8%), and take longer to relapse on immunosuppression discontinuation [131(37-216) 
vs. 14 (1-155) wks] (p=/<0.05). On KM analysis probability of poor outcome was similar in 
those with DIAIH and AIH (log rank test 0.339). On comparing those with (n=4) and without 
nitrofurantoin (n=7) DIAIH, the former were older (76.7+ 3.9 vs. 53.6 + 25.3 yrs), have 
longer duration of drug use prior to DIAIH diagnosis (36.0 +9.4 vs. 14.5 +12.7 mths), higher 
fibrosis stage (3.75 +2.1 vs. 2.3 +1.6) and less likely to relapse (0% vs. 100%) upon 
immunosuppression discontinuation.                                                                                                                                     
Conclusions:  About 15% of patients with AIH have DIAIH with similar outcomes though 
the latter are older with a propensity for late relapse, mandating long-term follow up. 
Key words: drug induced liver injury, nitrofurantoin, statins, herbal remedies 
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Introduction 
Autoimmune hepatitis (AIH) is a chronic disorder of unknown aetiology characterised by      
 presence of autoantibodies, hypergammaglobulinaemia, and interface hepatitis with about 
85% showing an excellent response to immunosuppression (1,2). 
A number of factors predict outcome in AIH including presence of cirrhosis, normal 
transaminases during follow up and ethnicity (3-6). Despite increasing interest in drug 
induced AIH (DIAIH), this remains an uncharacterised cohort with lack of consensus 
regarding diagnostic criteria, need for long-term immunosuppression and outcomes (7-11).  
This is mainly due to difficulty in differentiating between drug induced liver injury (DILI), 
immune DILI, DIAIH and coincidental drug use. Another contributing factor is that patients 
presenting with DILI can eventually develop AIH after varying periods of latency (11-13). 
The natural history of DIAIH is therefore controversial with some suggesting a benign course 
(absence of hepatic fibrosis and no relapse after immunosuppression discontinuation) (8), 
with others reporting advanced hepatic fibrosis and failure to maintain remission after 
discontinuation of prednisolone/azathioprine (7).  
The aim of this study therefore was to assess natural history and outcomes in patients with 
DIAIH and to further stratify natural history of DIAIH depending on the nature of the culprit 
drug. 
Patients and methods 
This retrospective cohort study included all patients with AIH being followed up between Jan 
2005 and Oct 2013 at a teaching hospital in southeast England, with last follow up recorded 
as of June 2014. Patients were identified via the electronic histopathology and clinic letters 
databases.  
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Autoimmune hepatitis was defined by criteria established by the International Autoimmune 
Hepatitis Group (14).                                                                                                                          
Study definitions 
• DIAIH:   
- Normal liver tests (if available) prior to drug initiation  
- No pre existing liver disease 
- Definite temporal association between drug initiation and subsequent diagnosis of 
AIH  
- Other causes for liver disease diligently excluded 
- Probable or definite by revised AIH criteria (14) 
- Roussel Uclaf Causality Assessment Method (RUCAM) score of highly probable (>8) 
or probable (6-8)(15) 
• Acute presentation: Bilirubin ≥ 5xULN and or ALT > 1000 IU/L. 
• Liver failure: Presence of any degree of hepatic encephalopathy and or international 
normalised ration (INR) ≥ 2 
• Remission: Normal ALT/resolution of symptoms, and if available normal IgG and histology  
• Relapse: ALT ≥ 2ULN with/without symptoms on treatment discontinuation 
• Poor outcome: Failure to achieve remission, liver failure (either at initial presentation or 
follow up), development of cirrhosis during follow up, development of cirrhosis 
complications, need for liver transplantation (LT) and/or liver related mortality (LRM). 
Cirrhosis related complications were defined as any one or more of the following: 
ascites/spontaneous bacterial peritonitis, high risk varices/variceal bleed, hepatocellular 
cancer and hepatic encephalopathy 
The exclusion criteria were 
• Overlap syndrome including biliary pathology such as primary biliary cirrhosis, 
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primary sclerosing cholangitis and autoimmune cholangitis.  
• Co existing liver disease due to alcohol, viral hepatitis, non-alcoholic fatty liver disease 
• Incomplete medical records 
A detailed review of the medical records (medical notes and electronic pathology and 
radiology database) was performed for those considered to have AIH and for each patient the 
following data was collected anonymously: demographics, autoantibodies (ANA, SMA, 
AMA, LKM), hepatitis serology, alcohol history, autoimmune hepatitis score [assessed by 
revised International Autoimmune Hepatitis Club diagnostic criteria (14), dose and duration 
of culprit drug (in cases of DIAIH), liver tests at onset, during remission and at last follow up 
and presence of additional autoimmune conditions.  
The liver biopsy report for each individual was reviewed and the following data collected: 
fibrosis stage (Ishak), presence of portal and lobular inflammation, and interface hepatitis,  
(all classified semi quantitatively as mild, moderate or severe), portal and lobular plasma 
cells, lymphocytes, neutrophils and eosinophils, collapse, necrosis, cholestasis  and rosettes 
(all as yes/no). 
In those individuals where the initial liver biopsy report was incomplete or unavailable, the 
biopsies were re reviewed by a dedicated local pathologist (MH) (see acknowledgement) 
Statistical analysis                                                                                                                              
Data are presented as mean standard deviation, median (interquartile range) or number (%) 
and all reported p values are two-tailed. The Mann-Whitney U and Student’s t tests were used 
to compare non-parametric and parametric continuous variables respectively and categorical 
data were compared using the 2 test/Fisher exact test. Kaplan-Meier (KM) curves were 
generated to assess probability of poor outcome in those with DIAIH and AIH. Statistical 
analyses were undertaken using SPSS Version 22 (Armonk, NY, IBM Corp).                                                                            
This study was classified as service evaluation by our Internal Institutional Ethical 
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Sponsorship Group and hence they determined that individual patient consent and formal 
National Research Ethics Approval were unnecessary. 
Results                                                                                                                                                              
During the study period 109 potential patients were identified. Of these 27 were excluded as: 
presence of overlap syndrome/biliary (n=17), coexisting liver disease (n=3)(non-alcoholic 
fatty liver disease n=2, chronic hepatitis C, n=1), drug induced liver injury (n=2), positive 
hepatitis E serology (n=1), and medical records not available (n=4). Eighty-two were 
therefore found suitable for the study. In 33(40.2%) the initial diagnosis of AIH had been 
made prior to 2005.                                                                                                                                                       
Table 1 shows the demographic data at entry in the whole cohort. Those with a positive 
autoantibody included 57 with positive ANA/SMA (one also LKM positive) and one with 
isolated positive LKM and one with  liver cytosol antibody. In 80 patients data was available 
to calculate pre treatment AIH scores:  35 (43.7%) were definite and 37 (46.2%) probable 
AIH. Seventy-six (92.7%) patients were treated of whom 71 (93.4%) achieved remission.  Of 
the six not treated (table 1) three had mild disease (included one with DIAIH who achieved 
spontaneous remission), three had likely “burnt out AIH” of whom one presented with 
variceal bleeding necessitating  a portocaval shunt, one underwent a LT, and one was listed 
for LT then delisted as stabilised (but eventually died). The median follow up for the whole 
cohort was 86.3 +61.8 mths with only 12 (14.6%) having < 18 mths follow up.                                                                                                                                                            
All  but two patients had undergone a liver biopsy at initial presentation. These two included 
a seventy-nine years old man with a pretreatment AIH score of 12 (biopsy attempted but 
unsuccessful) and a 13 year old with pretreatment AIH score of 17 (coagulopathy precluded 
biopsy). The original biopsy reports and liver biopsy samples were available in 72/80 (90 %) 
and 70/80 (78.7%) patients respectively. In the eight with no liver biopsy report available, the 
initial diagnosis had been made at an outside hospital of whom in four (50%) this was at a 
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regional transplant centre. Sixty of the 72 biopsies (83.3%) biopsies had either been reviewed 
by a dedicated local hisopathologist (MH) and or by two dedicated hisptopathologists (BP 
and AK) at the regional transplant centre (see acknowledgement). This included ten biopsies 
that were re reviewed by the local dedicated histopathologist (MH) as the original report was 
incomplete. 
Data in patients with DIAIH and AIH.                                                                                  
Of the 82 patients identified with AIH, 11 (13.4%) were considered to have DIAIH (table 2). 
RUCAM scores were probable for all 11 cases ranging between 6-8 (table 2). The implicated 
drugs were nitrofurantoin (n=4), statins (n=4), herbal remedies (n=2), and diclofenac (n=1).  
The herbal remedies included Echinacea (used for the common cold) and valerian (used for 
insomnia). All but two (18.1%) patients with DIAIH were female.  In eight (72.7%), baseline 
liver tests were normal prior to initiation of the offending drug, these being unavailable in 
three patients.  Hepatitis E serology was available in six (all negative).  Seventy percent with 
DIAIH had elevated IgG. The mean duration of drug use prior to diagnosis of DIAIH was 
23.1 +15.6 mths.  Eosinophilia was not reported in any of the 11 patients though two (patient 
no 4 and 11) developed a transient rash after use of concomitant drugs (salazopyrin and 
unknown antibiotic). However both already had symptoms/abnormal liver tests at time of 
initiation of   the concomitant drugs.  
Table 3 shows data in those with and DIAIH and AIH.  The former were more likely to be > 
60 years at presentation (p=0.048), score as probable AIH on revised criteria (p=0.012), and 
take longer time to relapse after discontinuation of immunosuppression (p=0.038). There 
were no significant differences as regards gender, liver tests at presentation, acute 
presentation, presence of other autoimmune conditions, symptoms, fibrosis stage and 
cirrhosis at onset, presence of portal/lobular inflammation, interface hepatitis, plasma cells, 
lymphocytes, eosinophils, neutrophils, collapse, cholestasis, rosettes and treatment schedules 
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(p>0.05)(table 3).  In 17/76  (22.4%) treated patients (two with DIAIH) additional drugs were 
used:  6-mercaptopurine (n=11, due to azathioprine intolerance); mycophenolate(n= 5,  in 
two azathioprine intolerance and in three suboptimal response to azathioprine); and 
cyclosporine (n=1, suboptimal response to azathioprine).  
In the AIH and DIAIH groups, median dose of prednisolone at onset was 30mg (5– 60)  and 
30 mg (10-40), (p=0.133) and 7.00mg (2.50 – 40) and 15.0mg (5 – 40) at last follow-up 
respectively (p=0.031).  Similarly, in the AIH and DIAIH groups, the median dose of 
azathioprine  at onset  was 50mg (50 – 150) and 50mg (50 – 100) (p=0.616) and 50mg (50 – 
200) and 50mg (50 – 100) at last follow-up respectively (p=0.572). 
Forty-two (51.2%) had other extra hepatic autoimmune disorders, though the prevalence was 
no different in those with DIAIH and AIH (table 3). These included thyroid disease(n=22), 
rheumatological conditions (n=13), dermatological disorders(n=3), autoimmune haemolytic 
anaemia n=2, gastrointestinal (ulcerative colitis/celiac disease, n=3), vasculitis (Churg-
Strauss/temporal arteritis, n=2) and extrinsic allergic alveolitis n=1.  Four (9.52%) had more 
than one extra hepatic autoimmune condition. Of the five patients with DIAIH and additional 
autoimmune conditions three had thyroid disease.  
Patients with nitrofurantion and non- nitrofurantoin DIAIH                                     
Comparing those with (n=4) and without nitrofurantoin (n=7) DIAIH, the former were older  
and had lower ALT but higher fibrosis stage at presentation.  The duration between drug 
initiation and detection of abnormal liver tests and duration between detection of abnormal 
liver tests and specialist review was longer in those with nitrofurantoin DIAIH. In all four 
cases with nitrofurantoin DIAIH, the drug was only discontinued after specialist review. This 
was in contrast to the non-nitrofurantoin group where in 74.1% (statins n=4 and diclofenac 
n=1) the drugs were discontinued by primary care physicians upon receipt of abnormal liver 
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tests (table 5). Despite shorter duration of immunosuppression prior to discontinuation none 
of the patients with nitrofurantoin DIAIH relapsed compared to all in the non-nitrofurantoin 
group (table 5).                                                                                                                   
Outcomes                                                                                                                                            
Overall 28 (34.1%) patients had a poor outcome (table 3 and 4). This included six (7.3%) 
with liver failure at onset of whom two also had cirrhosis, six (7.3%) developing cirrhosis 
during follow up  (confirmed histologically in five and radiologically in one), fifteen (18.3%) 
developing cirrhosis related complications (ascites n=9, hepatic encephalopathy, n= 3, 
variceal bleeding/high risk varices, n= 6), five (6.5%) failing to achieve remission and two 
(2.4%) undergoing LT (some had more than one event). Of those with cirrhosis related 
complications, 12 developed them at presentation and the remaining three during follow up. 
There were seven deaths (8.5%), one in DIAIH group, (non-LRM) and six in AIH group of 
which five (83.3%) were liver related.  
The two with DIAH and a poor outcome were an 82 year old lady with nitrofurantoin induced 
AIH (patient no 1) who had cirrhosis and ascites at onset (resolved with immunosuppression) 
with a non-LRM and a 19 year old with diclofenac induced AIH (patient no 4) who presented 
with acute liver failure (INR of 2.2), was transferred to the regional transplant centre but 
responded to medical treatment. Prevalence of poor outcome was lower in those with DIAIH 
(2/11, 18.2%) vs. those with AIH (26/71, 36.6%) though the differences were not statistically 
significant. However, none of the patients with DIAIH failed to achieve remission, developed 
cirrhosis during follow up, needed a LT or had a LRM (table 4).   Thirty patients (36.6%), 27 
with AIH and three with DIAIH had undergone more than one liver biopsy after a median 
interval of 30 mths (6-288). Overall 18 (60.0%) had stable fibrosis, five (16.7%) had 
reduction in fibrosis and seven (23.3%) had fibrosis progression- 0/3 (0%) with DIAIH and 
7/26  (26.9%) with AIH (p=0.548).  Even if just development of cirrhosis and need for LT 
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were considered as poor outcome there was still no statistically significant difference between 
those with DIAIH [0/11 (0%)] and AIH  [8/71 (11.27%)] (p=0.241). 
KM analysis showed that probability of a poor outcome was no different in those with DIAIH 
and AIH (log rank test 0.339) (fig 1). 
Discussion                                                                                                                                                                                      
In this retrospective cohort study we observed that approximately 15% of patients with AIH 
had DIAIH, the implicated drugs in three fourths being either nitrofurantoin or statins with 
herbal medication accounting for ~ 20% of the cases. The diagnosis of DIAIH was robustly 
made with all patients scoring as probable on the RUCAM scale. The natural history was 
similar in DIAIH and AIH especially as regards clinical presentation, presence of hepatic 
fibrosis, prevalence of cirrhosis and poor outcomes, and relapse rates. However, those with 
DIAIH were older (75% being above the age of 60 yrs), with a propensity for late relapse. 
This was despite those with DIAIH having a higher dose of prednisolone at last follow up. 
Finally, compared to the non-nitrofurantoin group, those with nitrofurantoin related DIAIH 
had more advanced fibrosis at presentation but lower risk of relapse on immunosuppression 
discontinuation. Increasing age is an established risk factor for DILI as also confirmed by 
Bjornsson et al’s recent population based study, where a two fold increase in crude annual 
incidence of DILI  (19.1- 39.9 /100,000) was observed in those < 25 yrs vs.  > 70 yrs (16). 
Drug dosage also predisposes to DILI and in the aforementioned study, 88% with DILI 
received daily doses > 50 mgs (16) compared with 75% of our cohort. 
Implicated drugs in this study [(nitrofurantoin, statins, diclofenac, and herbal remedies 
(echinacea, valerian)] have all previously been reported to cause DILI/DIAIH (17-28). Our 
reported frequency of DIAIH  (13.4%) is consistent with earlier studies (9.2-12%) (7,8). 
However, differentiating DIAIH from DILI or immune DILI can be challenging clinically 
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and histologically.  Suzuki et al reported that interface hepatitis, focal necrosis and portal 
inflammation, portal and intraacinar plasma cells, rosette formation and emperipolesis 
favoured AIH with portal neutrophils and intracellular cholestasis favouring DILI (29).  
However they observed indistinguishable histological features in AIH and DIAIH, which is 
consistent with our observation. Nonetheless, it must be noted that Suzuki et al observed poor 
concordance amongst four experienced histopathologists for DIAIH  (28.5%) compared to 
concordance of 46.4% for AIH, 42.1% for DILI (hepatocellular) and 50% for DILI 
(cholestatic/mixed) (29). Immune DILI and DIAIH are also indistinguishable clinically, 
though the former may be associated with a rash, eosinophilia, absence of hepatic fibrosis and 
lack of relapse on immunosuppression discontinuation (10).                                                                                                                   
Suzuki et al and Bjornsson et al’s data (8,29) does however suggest that the main histological 
feature that might differentiate AIH and DIAIH is lack of advanced fibrosis  (>metavir F2) in 
the latter. However we could not corroborate this as mean fibrosis stage (2.8 +1.8 vs. 3.6 
+2.0) and cirrhosis at presentation (27.2% vs. 35.2%) were no different in those with DIAIH 
and AIH. Even taking into account the six AIH patients that developed cirrhosis during 
follow up, the overall prevalence [3/11 (27.2%) vs. 31/71) (43.6%)] was still not statistically 
different in those with DIAIH and AIH. A possible explanation for these divergent results 
maybe that our patients were at least a decade older than Suzuki et and Bjornsson et al’s 
cohort (8,29) and advanced age is a predictor of more advanced hepatic fibrosis. However, 
Heurgue et al observed similar prevalence (57% vs. 48%) of F3-F4 fibrosis (metavir) in  
DIAIH and AIH despite a mean age of 47 years (7). Appleyard et al  (17) and the Spanish 
registry of Hepatotoxicity (30) have also reported presence of cirrhosis in DIAIH. Finally, in 
two recent reviews that included more than 100 cases of nitrofurantoin related DILI cirrhosis 
was not infrequently observed  (18,19). These data suggest that advanced hepatic fibrosis can 
be observed in DIAIH and should not negate against its diagnosis.  
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Another factor stated to differentiate DIAIH and AIH is lack of relapse upon discontinuation 
of immunosuppression in the former (8).  Our relapse rates, though lower in DIAIH (60% vs. 
83.3%) were not statistically different compared to the AIH group. Heurgue et al also 
reported a relapse rate of 42.8% in their cohort with DIAIH (7). In contrast, Bjornsson et al 
reported no relapses in 20 patients with DIAIH (included 11 with nitrofurnatoin and 9 with 
minocycline) (8), though it is conceivable that at least some had immune DILI where relapses 
are less likely (8,10). Additionally, the duration of follow up was uncertain in Bjornsson et 
al’s study (8). This maybe of relevance in view of our data showing a tendency for late 
relapse in DIAIH. Sugimoto et al have also reported seven DILI cases where liver tests did 
improve spontaneously upon cessation of the offending drug, with a subsequent flare that  
necessitated steroid treatment (11). Furthermore, Bjornsson et al observed AIH developing in 
22% after a mean of 5.8 years post hospitalisation with DILI (12). These data suggest that in 
patients with DILI/DIAIH, normalisation of liver tests  (either spontaneously or after use of 
immunosuppression) does not guarantee a benign course and highlights the need for 
prolonged follow up.                                                                                                                       
Stains and nitrofurantoin can cause both hepatocellular and cholestatic DILI as will as DIAIH 
(17-22). In a recent publication by the Drug Induced Liver Injury Network (DILIN), of the 22 
patients identified with statin induced DILI, 6 (27.2%) were considered to have DIAIH (20). 
They were older than those with hepatocellular DILI (62 +10.3) vs. 53 +9.8) with half 
requiring immunosuppression and documented relapse in at least one patient. About 50% had 
been on a statin for longer than 12 months, consistent with our data (duration of statin use 9-
36 months). In two reviews on nitrofurantoin DILI (19,20), 50% were above the age of 60 
yrs, and 54% had taken the drug for two years or longer with six deaths and one patient 
undergoing LT.  Bjornnson et al’s recent study observed DILI in 1:1369 patients using 
nitoufurantoin, confirming that this drug is a rare yet serious cause of hepatotoxicity (16).  
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We observed distinct differences between those with nitrofurantoin and non-nitrofurnatoin 
DIAIH.  The former had longer duration of drug use prior to detection of abnormal liver tests 
and on going drug use despite abnormal liver tests, factors associated with more severe DILI  
(31). This might be another explanation for the high prevalence of cirrhosis (50%) in this 
cohort. Interestingly all relapses occurred in the non-nitrofurantoin group though at present 
we are unable to offer an explanation for this.  
Our 20% prevalence of DIAIH due to herbal remedies is consistent with recent DILIN data 
where herbal and dietary supplements accounted for 15.5% of the DILI cases, the prevalence 
however significantly increasing from 7% to 20% during the study period  (2004-2013) (32). 
Valerian is a common herbal medication that is used to treat insomnia and a recent US survey 
showed about 5.6% of adults having used it in the past year (33). In 1989 MacGregor et al 
first reported valerian associated hepatotoxicity in a case series of 4 patients (of whom one 
had  advanced fibrosis) (25), this being followed by another case report (26). There have been 
warnings to avoid valerian in individuals with liver disease (34). There are two prior case 
reports of Echinacea associated hepatotoxicity including one with positive autoantibodies 
(27, 28). This study additionally highlights lack of awareness amongst healthcare 
professionals about the hepatotoxic potential of nitrofurantoin and herbal remedies as despite 
detection of abnormal liver tests both drugs were discontinued only after specialist review. 
Though prevalence of poor outcome was lower in those with DIAIH (18.2 vs. 36.6%), this 
was not statistically different, as was also supported by the KM analysis. However it is 
noteworthy that none with DIAIH failed to achieve remission, develop fibrosis progression, 
needed a LT and or had a liver related mortality.  
In conclusion the natural history of DIAIH appears to be similar to AIH especially as regards 
presence of advanced fibrosis at presentation and inability to maintain remission on 
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immunosuppression withdrawal, especially in the non-nitrofurantoin group. These data 
suggest that at least some patients with DIAIH mandate long-term follow up. Nonetheless, 
this needs corroboration by larger prospective studies. 
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Table 1. Data at entry in the whole cohort (n = 82) 
Age (yrs) 
>60 years 
55.40 ±16.54  
37 (45.1%) 
Caucasian  78 (95.1%) 
Female  66 (80.5%) 
Body mass index (kg/m2)  26.46 ±5.10 
Symptoms 68/79 (86.1%) 
Autoantibody positive 
ANA/SMA >80 
59/81 (72.8 %) 
50/76 (65.8%) 
Bilirubin (mg/dl) 
ALT (iu/l) 
Alkaline phosphatase (iu/l) 
Albumin (g/l) 
Globulins (g/l) 
Immunoglobulins 
Platelet count 
47.00 (5 – 530) 
480.00 (37 – 3480) 
221.6 ± 114.0 
37.1 ± 7.2 
43.6 ± 12.0 
23.8 ± 10.7 
227.7 ± 107.1 
Acute presentation 35 (42.7%) 
Fibrosis stage (index biopsy) 
Cirrhosis at onset  
3.47 +2.01 
28 (34.1%) 
Drug induced autoimmune hepatitis 11 (13.4%) 
Treated                                                                
Remission                                                            
Immmunosuppression discontinued                                         
Treatment duration before 
discontinuation (mths)                                                                   
Relapse 
76 (92.7%)                                                                 
71 (93.4%)                                                                      
17 (20.7%)                                                               
 20.1 +11.2                                                            
13/17 (76.4%) 
Poor outcome 28 (34.1%) 
Other autoimmune conditions 42/81 (51.8%) 
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Table 2: Data in patients with drug induced autoimmune hepatitis 
No 
Age/
Sex 
Drug ,dose, 
duration 
ANA/ 
SMA 
AIH 
Score  
Bilirubin 
mol/l 
ALT 
iu/l 
INR Fibrosis 
stage 
(Ishak) 
RUCAM 
score 
Treatment  Treatment 
stopped                                  
1 
82F 
Nitrofurantoin 
50 mg              
35 mths 
1:640 12 32 115 1.2 6 8 prednisolone 
and 
azathioprine 
yes after 12 
mths, no relapse 
2 
75F 
Nitrofurantoin 
50 mgs,            
36 mths   
1:1280 10  94 587 1.5 5 7 prednisolone 
then 
azathioprine 
yes after 17 
mths, no relapse 
3 
73M 
Nitrofurantoin 
100 mg           
48 mths             
- ve  10 15 178 1.1 2 8 prednisolone 
then 
azathioprine/ 
6MP 
no 
4 
19F 
Diclofenac, 50 
mg thrice 
daily 
2 mths 
1:320 
 
11 461 3480 2.2 1 8 prednisolone 
and 
azathioprine 
no 
5 
63F 
Simvastatin*  
18 mths 
-ve 11 15 1245 1.3 5 8 prednisolone  
then 
azathioprine 
no 
6 
73F 
Atorvastatin 
20 mgs              
9 mths 
1:640 
 
15 10 721 1 2 8 None, 
spontaneous  
remission 
 
7 
56/M 
Echinacea     
dose/ duration 
unknown 
1:640 12 258 1200 1.1 4 6 prednisolone  
then 
azathiorpine 
yes after 36 
mths, relapsed 
and re treated 
8 
69F 
Simvastatin, 
dose unknown 
 36 mths 
1:200 16 21 314 1 1 8 Prednisolone 
only 
yes after 16 
mths, relapsed 
and  retreated 
9 
78F 
Atorvastatin 
20 mg             
19 mths            
1:640 17 45 640 1.1 2 8 Prednisolone 
only 
yes after 24 
mths , relapsed 
and retreated 
10 
17F 
Valerian, dose 
unknown 
3 months 
1:320 12 69 1468 1.1 1 7 prednisolone 
then 
azathioprine 
no 
11 
77F 
Nitrofurantoin 
50-100 mgs        
25 mths 
- ve 14 116 429 1.1 2 8 prednisolone 
then 
azathioprine/ 
6MP 
no 
* In a drug trial so received either 20 mg or 80mg simvastatin 
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Table 3. Data in patients with drug induced autoimmune hepatitis (DIAIH) and  autoimmune hepatitis (AIH)  
 DIAIH (n=11) AIH (n=71) P value 
Female 
Age 
Age > 60 years 
BMI 
Other AI conditions 
9 (81.8%) 
55.04 +15.2 
8 (72.7%) 
24.3 + 5.14 
5 (45.4%)  
57 (80.3%) 
62.0 +22.9 
29 (40.8%)  
26.9 + 6.11 
37/70 (52.8%) 
0.635 
0.156 
0.049 
0.200 
0.447 
Acute presentation 
Symptoms 
6 (54.5%) 
11 (100%) 
33 (46.5%) 
57/68 (83.8%) 
0.618 
0.170 
Duration of symptoms (days) 
Duration between abnormal liver 
tests and specialist review (wks) 
84.0 (3 – 120) 
8 (0.5-40) 
 
23.0 (1 – 728) 
6 (0.14-140) 
 0.185 
 
Definite AIH pre treatment  
Probable AIH pre treatment  
2 (18.2%)  
9 (81.8%)  
33/69 (47.8%) 
28/69 (40.5%) 
 0.062 
0.012 
Billirubin (µmol/dl) 
at entry 
at remission 
 
57.0 (15 – 461) 
12 (9-23) 
 
 
51.0 (5 – 481) 
8(4-38)  
 
0.874 
0.428 
ALT (iu/l) 
at entry 
at remission 
ALT/AST > 10 ULN 
 
613.0 (115 – 3480) 
29.9 +12.0 
8 (72.7) 
 
512.0 (37 – 2990) 
27.1 +11.7 
35 (49.2%) 
 
 0.324 
 0.635 
0.160 
ALP (iu/l) 
at entry 
at remission 
 
268.2  ±149.1 
86.4.0 ± 37.7 
 
214.8 ±142.9 
88.3 ± 48.2 
 
 0.250 
 0.908 
Globulin (g/dl)  
at entry 
at remission 
 
40.4 ±6.5 
30.3 ± 4.7 
 
 
44.0 ±12.4 
32.8 ± 9.3 
 
 
0.455 
 0.433 
 
IgG (g/L) 
at entry 
at remission 
Globulins/IgG elevated at onset 
 
 
21.4 ±7.5 
11.1 ±2.2 
8/11 (72.7%) 
 
 
24.3 ±11.2 
12.8 ±3.2 
52/69 (75.4%) 
 
 
0.422 
0.193 
0.851 
 
Albumin (g/L)  
at entry 
at remission 
 
 
36.1 ±5.1 
39.4 ±4.0 
 
36.7 ±7.1 
41.2 ±4.9 
 
 
0.798 
 0.250 
 
INR  
at entry 
at remission 
 
1.2 ±0.3 
1.0 ±0.1 
 
 
1.3 ±0.3 
1.2 ±1.2 
 
 
 0.760 
0.233 
Fibrosis score at index biopsy 
Cirrhosis at onset (Ishak 5-6) 
Histology 
2.8 +1.8 
3/11 (27.2%) 
3.6 +2.0 
25/71 (35.2%) 
 
0.250 
0.442 
 
Moderate to severe portal 
inflammation 
Mod to severe interface hepatitis 
Mod to severe lobular hepatitis 
9 (81.8%)  
 
6 (54.5%) 
7 (63.6% 
51/62 (82.2%) 
 
39/61 (63.9%) 
36/61 (59.0%)  
0.972 
 
0.554 
0.567 
Portal plasma cells 
Lobular plasma cells 
Portal lymphocytes 
Lobular lymphocytes 
Portal neutrophils 
Lobular neutrophils 
Portal eosinophils 
Lobular eosinophils 
Collapse 
9 (81.8%) 
7 (63.6%) 
9/10 (90%) 
9/10 (90%) 
4/10 (40%)  
4/10 (40%) 
5/10 (50%) 
4/10 (40%) 
3 (27.2%) 
55/61 (90.2%) 
43/61 (70.5%) 
51/61 (83.6%)  
51/60 (85.0%) 
24/60 (40%) 
18/60 (30%) 
21/61 (34.4%) 
16/60 (26.7%) 
17/60 (28.3%) 
0.353 
0.448 
0.195 
0.563 
0.641 
0.385 
0.272 
0.304 
0.628 
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Cholestatis 
Rosettes  
1 (9.1%) 
3 (27.2%) 
9/62 (14.5%) 
13/61 (16.4%) 
0.532 
0.461 
Treated 
Prenisolone then azathioprine 
Prednisolone+azathioprine 
Prednisolone montherapy 
10 (90.9%) 
7/10 (70%) 
2/10 (20%) 
1/10 (10%) 
66 (92.9%) 
46/66 (69.7%)  
9/66 (13.6%) 
10/66 (15.1%) 
0.591 
0.610 
0.444 
0.556 
Remission 
Time to remission (wks)            
10 (100%) 
8.00 (2 – 16) 
61 (92.4%) 
14.00 (2 – 120) 
 0.484 
0.321 
 
Relapse 
Time to relapse (weeks) 
Duration of immunosuppression 
before discontinuation (mths) 
3/5 (60%)   
131 (37-216) 
19.8 +11.5 
10/12 (83.3%)  
14 (1–155) 
20.2 +11.6 
0.538 
0.033 
0.943 
Poor outcome 2 (18.2%) 26 (36.6%) 0.316 
One patient with AIH treated with azathioprine monotherapy 
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Table 4. Details of poor outcome events in those with drug induced autoimmune hepatitis (DIAIH) and  
autoimmune hepatitis (AIH)   
Event  DIAIH (n=11) AIH (n=71) p value 
Liver failure at onset 1 (9.1%) 5 (7.0%) 0.591 
Developed cirrhosis during follow 
up 
0 (0%) 6 (8.4%) 0.409 
Developed cirrhosis related 
complications 
1 (9.1%) 14 (19.7%) 0.357 
Failure to achieve remissions  0/10 (0%) 5/66 (7.5%) 0.484 
Need for liver transplant 0 (0%) 2 (2.8%) 0.748 
Liver related mortality 0 (0%) 5 (7.0%) 0.650 
 
Some patients had more than one event 
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Table 5: Nitrofurantoin vs. non-nitrofurantoin drug induced autoimmune hepatitis (DIAIH) 
 Nitrofurantoin DIAIH  
(n=4) 
Non-nitrofurantoin DIAIH 
(n=7) 
Age (yrs) 76.7 +3.9 53.6 +25.3 
Duration of drug use prior to   
abnormal liver tests 
Drug discontinued prior to 
specialist review 
36.0 +9.4  
0 (0%) 
0/4 (0%) 
14.5 +12.7  
5 (71.4%) 
5/7 (71.4%) 
Duration between abnormal liver 
tests -specialist review (wks) 
16 (4-80) 6 (0.5-20) 
ALT (iu/l) 303 (115-587) 721 (640-1468) 
Increase globulins/IgG 4 (100%) 4 (57.1%) 
Definite AIH 0 (0%) 2 (28.5%) 
Cirrhosis at onset 
Fibrosis stage 
2 (50%) 
3.75 +2.1  
1 (14.3%) 
2.3 +1.6 
Portal/lobular neutrophils 
Lobular eosinophils 
Rosettes 
0/3 (0%) 
0/3 (0%) 
3/4 (75%) 
4 (57.1%) 
4 (57.1%) 
0/7 (0%) 
Immunosuppression discontinued 
Duration of immunosuppression  
before discontinuation (mths)   
Relapse 
2/4 (50%) 
 
11.5 +7.8  
0/2 (0%) 
3/6 (50%) 
 
20.0 + 8.5                                                             
3/3 (100%) 
 
 
 
 
 
 
 
 
 
 
 
